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RNA interference (RNAi) is an endogenous cellular process in which
small double-stranded RNAs lead to the destruction of mRNAs with com-
plementary nucleoside sequence. With the production of RNAi libraries,
large-scale RNAi screening in human cells can be conducted to identify
unknown genes involved in a biological pathway. One challenge researchers
face is how to deal with the multiple testing issue and the related false
positive rate (FDR) and false negative rate (FNR). This paper proposes
a Bayesian hierarchical measurement error model for the analysis of data
from a two-channel RNAi high-throughput experiment with replicates, in
which both the activity of a particular biological pathway and cell viability
are monitored and the goal is to identify short hair-pin RNAs (shRNAs)
that affect the pathway activity without affecting cell activity. Simulation
studies demonstrate the flexibility and robustness of the Bayesian method
and the benefits of having replicates in the experiment. This method is illus-
trated through analyzing the data from a RNAi high-throughput screening
that searches for cellular factors affecting HCV replication without affect-
ing cell viability; comparisons of the results from this HCV study and some
of those reported in the literature are included.
1. Introduction.
1.1. RNA interference high-throughput screening and the motivating ex-
ample. RNA interference (RNAi) is a conserved biological pathway by which
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messenger RNAs are targeted for degradation by double stranded RNA of
identical sequence and, thus, it silences gene expression on the level of indi-
vidual transcripts [Chapman and Carrington (2007), Fire et al. (1998)]. For
example, in mammalian cells, small interfering RNAs (siRNAs) are effective
in silencing target mRNAs [Echeverri et al. (2006), Elbashir et al. (2001),
Hannon and Zamore (2003)]. Initially, it was used to knockdown the func-
tion of individual genes of interest; with the production of RNAi libraries,
it is possible for the current technology to silence most of the genes in the
genome and conduct genome-wide loss-of-function screening so as to iden-
tify previously unknown genes involved in a biological pathway; it provides
a systematic analysis of the genome. The purpose of RNAi high-throughput
screening (HTS) is to identify a set of siRNAs affecting the cellular pheno-
type of interest; in the HTS literature, this is referred to as hit selection.
For example, RNAi technology has opened up the field of genomic scale cell-
based screening to the study of viral-host interactions [Cherry (2009)] and
several RNAi HTS have been conducted to identify cellular factors required
for various viral infections.
As Boutros and Ahringer (2008) and Echeverri et al. (2006) pointed out,
while RNAi HTS is promising and has generated various significant tech-
nical advances and scientific findings, there are still challenges regarding
high-throughput assay development and data analysis. In particular, Cherry
(2009) and Tai et al. (2009) remarked that in the studies of viral-host inter-
actions, while RNAi HTS has led to the discovery of hundreds of new factors
and increased our knowledge of the host factors that impact viral infection
and highlighted the cellular pathways at play, there is a surprising lack of
concordance between the results of seemingly similar screens. Among issues
to be considered when comparing these studies, one recognizes the need to
standardize the statistics methods and to address the false positive and false
negative rates inherent to high-throughput siRNA screens.
We note that RNAi HTS refers to a wide range of different experiments.
To determine the assay appropriate for the biological process to be investi-
gated and to choose or develop statistical methods suitable for data result-
ing from the experiments are of great importance; see Boutros and Ahringer
(2008). More specifically, this paper treats the simple situation that uses
cell-based homogeneous assay, in which the phenotypes of many cells are
averaged across each well in a microtitre plate. In particular, we are inter-
ested in data generated from a two-channel cell-based RNAi HTS experiment
where the phenotype of a pathway-specific reporter gene and that of a con-
stitutive reporter are measured; such experimental setups are typically used
in screens for signaling pathway components; see page R66.5 of Boutros,
Bras and Huber (2006). Typical examples include RNAi HTS experiments
designed for the identification of cellular factors required for viral infections,
in which cell viability is measured and used to account for the effect of
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unequal cell numbers in different wells on the measurements of virus RNA
replication.
This experimental setup makes it possible to distinguish changes in the
readout caused by depletion of the specific pathway components and changes
incurred by the changes in the overall cell number. Based on the plot for
a two-channel RNAi HTS experiment, Boutros, Bras and Huber (2006) sug-
gest, for a given siRNA, the ratio of the log of the readout of the specific
pathway to the log of the overall cell number is used as a summary of the
effect of the siRNA on the specific pathway. In the analysis of data from
RNAi HTS to identify host factors involved in HIV-1 replication, Bo¨rner
et al. (2010) also carried out log transformation of the raw data, including
both the measurement of the pathway activity and the cell count in each
well, and applied a robust locally weighted regression [Cleveland (1979)] to
smooth the scatterplot of the log transformed data. In a sense, this seems
to be an extension and improvement of the suggestion of Boutros, Bras and
Huber (2006).
To make a more systematic use of the data, we propose a Bayesian regres-
sion model that treats cell viability as a covariate and the specific pathway
activity measurement as the response variable so that the pathway activity
change can be studied in terms of the regression coefficient and the issues
of false positive and false negative rates can be handled in the Bayesian
framework.
Statistical methods for cell-based RNAi HTS have been introduced and
reviewed by Boutros, Bras and Huber (2006), Zhang et al. (2006), Zhang
et al. (2008), Malo et al. (2006) and Birmingham et al. (2009), among others.
Most of them deal with one-channel screening and use descriptive quantities
like fold change or simple statistics like Z-score or t-test to identify a set
of siRNAs that inhibit or activate defined cellular phenotypes. The only
exceptions are Zhang et al. (2008), who proposed a Bayesian method for
one-channel screening experiments to handle false positive and false negative
rates, and Boutros, Bras and Huber (2006), who included some discussions
on two-channel experiments.
Another feature of our experiment is that for each siRNA, the experiment
is replicated in 2J wells, where J of them measure cell viability and the
other J measure the specific pathway activity. We note that Tai et al. (2009)
is an example of two-channel RNAi HTS with J = 2 replicates, with pooled
siRNAs though, and that the dual channel experiment mentioned in Boutros,
Bras and Huber (2006) also has J = 2 replicates. Our method will make use
of these replicates.
Our method is motivated by the following RNAi HTS that searches for the
cellular factors that affect HCV replication without affecting cell viability,
referred to as the HCV study in this paper. HCV (hepatitis C virus) is
a small, enveloped, positive-sense single-stranded RNA virus of the family
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Flaviviridae and the cause of hepatitis C in humans; see Ryan and Ray
(2004). It is estimated that hepatitis C has infected nearly 200 million people
worldwide, and is now infecting 3 to 4 million people per year (WHO, see
the URL below). It is currently a leading cause of cirrhosis, a common cause
of hepatocellular carcinoma. As a result of these conditions, it is the leading
reason for liver transplantation in, for example, the United States (NIDA,
see the URL below).
The experiment is carried out as follows. A Huh-7-derived HCV-Luc
cell line that contains the genome of the HCV and harbors the luciferase
gene as a reporter is employed as a cell-based system for RNA interfer-
ence screening. We have shown that luciferase activity correlates well with
the HCV replication (data not shown). The HCV-Luc cells are transduced
by the lentiviruses each carrying specific short-hairpin RNA (shRNA) and
puromycin-resistant gene. In these circumatances, lentivirus-transduced cells
survive under puromycin selection. HCV RNA replication in the well can
now be measured in terms of the expression of luciferase in HCV-Luc and
cell viability in the well can be measured by a colorimetric method which
monitors the level of dehydrogenase in viable cells.
A VSV-G pseudotyped lentivirus-based RNAi library targeting a whole
panel of human kinases and phosphatases was employed [Moffat et al. (2006)]
in this study. This library includes 6,390 shRNAs designed to target 1,187
genes. HCV-Luc cells are seeded in 96-well plates and each well is transduced
with one of these 6,390 shRNAs. There are in total 71 plates and each plate
has about 6 wells for the controls. There are three types of controls: spike
negative (SN), no transduction no puromycin selection (NTNP), and no
tranduction with puromycin selection (NTWP). In SN control wells, the
nonhuman gene targeting shLacZ is used instead of the above-mentioned
shRNAs; data from these wells serve as the RNAi machinery competition
controls. In NTNP control wells, cells are not transduced by lentiviruses
nor subjected to puromycin selection. In NTWP control wells, cells are not
transduced by lentiviruses but subjected to puromycin selection. There are
in total 142 SN wells with most plates having 2 SN wells in each plate, 217
NTNP wells with most plates having 3 NTNP wells in each plate and 67
NTWP wells with most plates having one NTWP well in each plate. It is
believed that in both SN and NTNP wells, we should observe normal HCV
RNA replication and in NTWP wells, we should observe little HCV RNA
replication and minimal cell viability.
The experiment described in the previous two paragraphs is replicated
four times in a plate-by-plate manner; specifically, for each plate, there are
three replicated plates in the sense that wells at the same position in these
four plates are transduced by the same shRNA. We call this platewise repli-
cation. Among these four plates, we use two of them to measure cell viability
and the other two to report luciferase activity as a surrogate for HCV RNA
replication assay.
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(a) (b)
Fig. 1. Plots for the HCV study data after preprocessing. There are in total 6,130 data
points with the 419 controls excluded. (a) On the original measurement scale; (b) on the
log transformed scale.
1.2. A log-linear measurement error model. Let x˜ij denote the measure-
ment of the cell viability in the jth well of the ith shRNA. Let y˜ij denote the
measurement of the pathway activity in the (J+ j)th well of the ith shRNA.
Here i= 1, . . . , I and j = 1, . . . , J with J > 1. In practice, both x˜ij and y˜ij
refer to the measurements undergone in certain data preprocessing steps so
as to have reduced systematic bias. Figure 1 gives the data plot; Figure 1(a)
is a plot of the data from the above HCV study with x˜ij and y˜ij , respectively,
the horizontal and vertical coordinates for I = 6,549 and j = 1; Figure 1(b)
is the corresponding plot for log x˜ij and log y˜ij . Visual examination of Fig-
ure 1(a), (b) suggests that a linear model on the logarithm transformed data
is considered. In fact, the Additional data file 4 in Boutros, Bras and Hu-
ber (2006) also suggests the consideration of logarithm transformed data in
a two-channel experiment based on their data. Another reason for this loga-
rithm transformation is that based on Q–Q plots, both log x˜i1 − log x˜i2 and
log y˜i1 − log y˜i2 are, respectively, much closer to normal distributions than
x˜i1 − x˜i2 and y˜i1 − y˜i2. In fact, we found that logarithm transformation is
very close to those suggested by the Box–Cox transformation [Box and Cox
(1964)] technique.
Motivated by the above exploration, we assume that there exist µi and νi
such that log(x˜i1)−µi and log(x˜i2)−µi are independent with mean zero and
likewise log(y˜i1)− νi and log(y˜i2)− νi are also independent with mean zero.
We note that this formulation takes advantage of the replication in the
experiment design and eµi and eνi represent, respectively, the expected cell
viability and pathway activity when transduced by the ith shRNA. For the
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ith shRNA, denote by γi = 0 if it incurs no change on the pathway activity,
and by γi = 1 if it does; in case γi = 1, the magnitude of the change is
represented by βi. γi is usually called the model index parameter. The plot
in Figure 1(b) suggests a linear relation between νi and µi and the following
simple relation
νi = α0 + γiβi + α1µi(1)
is assumed in this paper, which seems to be one of the simplest that can
be reasonably imposed on the relation between pathway activity and cell
viability. In the context of the HCV study, (1) is a simple way to account for
the effect of cell numbers on HCV replication. We note that the HCV infects
the host cell and replicates in it, therefore, the number of cells in a well can
affect the total number of HCV virion in that well; the purpose of measuring
cell viability in each well is to account for this effect on HCV replication.
We regard (1) as a statistical formulation to refine and implement the idea
of Boutros, Bras and Huber (2006) and Bo¨rner et al. (2010) mentioned in
Section 1.1. In the original measurement scale of Figure 1(a), it says the
pathway activity eνi is a monomial of the cell viability eµi with coefficients
involving a baseline constant α0, activity change indicator γi, and activity
change coefficient βi:
eνi = eα0+γiβi · eα1µi .
To complete the likelihood specification, we consider the robust and flex-
ible model which assumes t-distributions for each shRNA:
xij ≡ log(x˜ij) = µi+ εxij/√ωxij ,
(2)
yij ≡ log(y˜ij) = νi + εyij/√ωyij .
Here εxij , εyij , ωxij , and ωyij are independent, εxij and εyij have normal
distributions N (0, σ2xi) and N (0, σ2yi), respectively, and ωxij and ωyij have
gamma distributions Ga(dx/2,2/dx) and Ga(dy/2,2/dy), respectively. We
note that the error terms εxij/
√
ωxij and εyij/
√
ωyij have t-distributions
with degrees of freedom, respectively, dx and dy and scale parameters, re-
spectively, σ2xi and σ
2
yi .
Discussions on error terms of the form (2) and their advantages appeared
in the gene expression literature; see, for example, Gottardo et al. (2006),
Lewin et al. (2006) and Lo and Gottardo (2007). The idea is that a hierar-
chical t-formulation makes the model more robust to outliers than the usual
Gaussian model and an exchangeable prior for the variance allows each
shRNA to have a different variance and hence makes it more flexible.
Let γ = (γ1, . . . , γI), β = (β1, . . . , βI), µ= (µ1, . . . , µI), σ
2
x = (σ
2
x1 , . . . , σ
2
xI
),
σ2y = (σ
2
y1 , . . . , σ
2
yI ), ωx = (ωx1 , . . . , ωxI ) ≡ ((ωx11 , . . . , ωx1J ), . . . , (ωxI1 , . . . ,
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ωxIJ )), ωy = (ωy1 , . . . , ωyI ) ≡ ((ωy11 , . . . , ωy1J ), . . . , (ωyI1 , . . . , ωyIJ )), x = (x1,
. . . , xI)≡ ((x11, . . . , x1J), . . . , (xI1, . . . , xIJ)), and y = (y1, . . . , yI)≡ ((y11, . . . ,
y1J), . . . , (yI1, . . . , yIJ)). To study the likelihood, it seems easier to consider
the conditional density of (x, y) given ωx and ωy or the joint density of (x, y),
ωx, and ωy. In fact, the former has the closed form:
f(x, y|γ,β,µ,α0, α1, σ2x, σ2y, ωx, ωy)
=
I∏
i=1
J∏
j=1
√
ωxij
2piσ2xi
exp
{
−1
2
(
xij − µi
σxi/
√
ωxij
)2}
×
√
ωyij
2piσ2yi
exp
{
−1
2
(
yij −α0 − γiβi −α1µi
σyi/
√
ωyij
)2}
.
The latter is equal to
g(x, y,ωx, ωy|γ,β,µ,α0, α1, σ2x, σ2y , dx, dy)
= f(x, y|γ,β,µ,α0, α1, σ2x, σ2y , ωx, ωy)
(3)
×
I∏
i=1
J∏
j=1
(dx/2)
dx/2
Γ(dx/2)
ωdx/2−1xij exp
{
−dx
2
ωxij
}
× (dy/2)
dy/2
Γ(dy/2)
ω
dy/2−1
yij exp
{
−dy
2
ωyij
}
.
These expressions are useful in the implementation of Bayesian analysis.
1.3. Organization of this paper. Based on the log-linear measurement
error model that allows error terms having shRNA specific t-distributions,
we will take a Bayesian hierarchical approach to analyze the data from the
HCV study, which is a typical viral-host interaction study using cell-based
RNAi HTS. Our purpose is to propose shRNA lists and associated false
positive rates so that experimental scientists can decide whether to follow
up with functional or biological studies.
Section 2 points out the quantities that are of primary interest and indi-
cates the way to introduce the priors and the joint density used for poste-
rior inference; the hybrid MCMC for sampling the posterior density is too
complicated and is postponed to the supplementary material [Chen et al.
(2011)]. Section 3 presents simulation studies to demonstrate that models
having shRNA specific t-distributions outperform models assuming constant
variance Gaussian error terms and to explore the extra-power a RNAi HTS
with replicates has in identifying shRNAs affecting pathway activity and
in estimating the false discovery rates. Section 4 summarizes the data pre-
processing procedures for data from RNAi HTS; these include edge effect
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adjustment, normalization, and outlier removal. Section 5 analyzes the data
from the HCV study. In addition to illustrating the methods in real data
analysis, evaluating the performance of the methods by negative control
wells, and proposing shRNA lists with associated false discovery rates, we
compare our results with those from a limited Q-PCR study and those us-
ing the standard Z-score method; we also compare our results with those
from similar RNAi HTS in the literature. The former indicates that results
based on our methods are in better agreement with those based on Q-PCR
than those based on Z-score are and the latter spotted some common find-
ings, which is encouraging in view of the lack of concordance in this area
pointed out in Cherry (2009). Section 6 gives a brief discussion of future
investigations.
2. Bayesian inference. With the likelihood in (3), we now describe a hi-
erarchical model for Bayesian inference. The following quantities are of pri-
mary interest. The posterior probability that γi = 0 given the data, denoting
pi = P (γi = 0|x, y), reports the probability of incurring no activity change
by the ith shRNA; smaller pi suggests larger probability of incurring ac-
tivity change; 1− pi gives the probability of incurring activity change. The
marginal posterior distribution of βi indicates the amount of positive or neg-
ative influence on the pathway activity given that there is activity change,
which is denoted by pi(βi|γi = 1, x, y). We will see in our real data analysis
that E(βi|γi = 1, x, y) is highly correlated with pi = P (γi = 0|x, y) and is
often very useful in providing a list for further study.
The priors on (γ, β), µ, α0, α1, σ
2
x, σ
2
y , dx, and dy are independently assig-
ned. Let N(·|0, V ) denote the normal density with mean zero and variance V .
Let IG(·|A,B) denote the inverse gamma density with shape parameter A
and scale parameter B. The prior on σ2x is defined by assuming σ
2
x1 , . . . , σ
2
xI
an i.i.d. sequence with density IG(σ2xi |Ax,Bx) and that on σ2y is defined simi-
larly by assuming σ2y1 , . . . , σ
2
yI
an i.i.d. sequence with density IG(σ2yi |Ay,By).
Let Ax = a
2
x/bx +2, Bx = (a
2
x/bx +1)ax, Ay = a
2
y/by +2, and By = (a
2
y/by +
1)ay , then σ
2
xi has mean ax and variance bx and σ
2
yi has mean ay and vari-
ance by. The prior is assigned by assuming ax, bx, ay, and by are inde-
pendent with uniform distribution U(0, φ1), U(0, φ2), U(0, φ3), and U(0, φ4),
respectively. We note that while the model allows shRNA specific variance,
information is shared between them through these distributions so as to
stabilize the variances. We will make use of the fact that we have repli-
cates in the experimental design to choose φ1 and φ2. Roughly speaking,
we choose φ1 (φ2) equal to or larger than twice the sample mean (sample
variance) of {(xi1 − xi2)2/2|i = 1, . . . , I}, because we wish to have a more
vague prior. The way to choose φ3 and φ4 is similar. The prior for dx and dy
are uniform on the integers from 1 to 100.
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The prior on γ is defined by assuming γ1, γ2, . . . , γI an i.i.d. sequence with
P (γi = 0) = 1−P (γi = 1) = p, which is assumed to have a density Beta(φ5, φ6).
If γi = 0, let βi = 0; otherwise, let βi have a density N(βi|0, V ). Both α0
and α1 also have prior densities N(α0|0, V ) and N(α1|0, V ). We assume V
has inverse gamma density IG(V |φ7, φ8). The parameters (φ5, φ6) studied
are (9,1) and (1,1); we will see in Section 5.5 that the posterior inferences
do not seem to be sensitive to the values of (φ5, φ6). We choose φ7 and φ8
to make IG(V |φ7, φ8) have large mean and variance so that it is less infor-
mative. We note that the prior on (γi, βi) follows and extends that in Scott
and Berger (2006) for microarray gene expression studies.
The prior for µ is defined by assuming µ1, µ2, . . . , µI an i.i.d. sequence
with uniform distribution U(−3,1), which is motivated by the fact that in the
HCV study, log(x˜ij) belongs to (−3,1) for every i and j; see Figure 1(b).
Section 5.5 also shows that our main results do not vary much with the
changes in the prior on µ.
In addition to the above rationale, we limit our attention to the priors for
which the models fit the data well by posterior predictive check, discussed
by Gelman, Meng and Stern (1996). In case there are several models fitting
the data well, we prefer the less informative priors.
It follows from (3) in Section 1.2 that the joint density of (x, y, ωx, ωy,
γ, β, µ, α0, α1, σ
2
x, σ
2
y , dx, dy , p, V , ax, bx, ay, by) is
g(x, y,ωx, ωy|γ,β,µ,α0, α1, σ2x, σ2y, dx, dy)
× pI−
∑I
i=1 γi+φ5−1(1− p)
∑I
i=1 γi+φ6−1
×
I∏
i=1
(N(βi|0, V ))γi ·N(α0|0, V ) ·N(α1|0, V ) · IG(V |φ7, φ8)(4)
×
I∏
i=1
IG(σ2xi |Ax,Bx)J(Ax,Bx)
×
I∏
i=1
IG(σ2yi |Ay,By)J(Ay,By),
where J(·, ·) is the Jacobian matrix of the transformation from (A,B) =
(a2/b+ 2, (a2/b+ 1)a) to (a, b). It is based on (4) that we propose a hybrid
MCMC algorithm for computing the posterior distribution [see, e.g., Robert
and Casella (2004), page 393]. We note that we use the trick to update γi
after integrating out βi to make the algorithm more efficient; see Gottardo
and Raftery (2009). Several useful observations that accelerate the hybrid
MCMC algorithm and the algorithm itself are given in the supplementary
material [Chen et al. (2011)] to streamline the presentation.
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3. Simulation studies. The purposes of these simulation studies are to
evaluate the performance of our Bayesian method and to indicate the ben-
efits of having replicates in a RNAi HTS experiment. Our studies show
that the hierarchical model allowing error terms having t-distributions and
shRNA specific variance outperform the usual Gaussian model with fixed
common variance in terms of study power and false positive rate estimation.
The first data set we study is generated as follows. The total number of
shRNAs is 6,130. The number of replicates is 2. The model index parame-
ter γi is equal to 1 for i = 1, . . . ,100, and equal to 0 for i > 100. If γi = 0,
then βi = 0; otherwise generate βi from uniform distribution on (−5,3). Let
the parameters µi be generated by (0.248 + 2.77) · Beta(6,2)− 2.77, which
has support on (−2.77,0.248) and is very close to the empirical distribution
of {xij} in the HCV study. Let α0 = 12.557, α1 = 2.538, dx = 3, and dy = 3.
Let σ2xi be IG(σ
2
xi |3,0.2), which has mean 0.1 and variance 0.01, and σ2yi be
IG(σ2yi |3,1), which has mean 0.5 and variance 0.25; we note that these means
and variances are many times larger than those suggested by the data in the
HCV study, given in Section 5.1. In fact, some aspects of the data set are
chosen deliberately so they are similar to those in the HCV study and some
are chosen to be distinguished from those in the model or prior specifications
in the previous sections. The aspects similar to the HCV study include the
number of shRNAs, the number of replicates, and the distribution of the cell
viabilities. These help to make the simulation studies relevant to real data
analysis and are useful for the study of robustness of our method.
Our first analysis uses the model and prior described earlier in Sections 1.2
and 2; in particular, we choose φ1 = φ2 = φ4 = 0.2, φ3 = φ6 = 1, φ5 = 9,
φ7 = 3, and φ8 = 30,000. For the second analysis, we use the model in Sec-
tion 1.2 with ωxij = ωyij = 1, σ
2
xi = σ
2
x, and σ
2
yi = σ
2
y , both of which are
estimated from the data, and a constant V , which is equal to the posterior
mean of the V obtained in the first analysis. We summarize the comparison
of these two analyses in Figure 2, in which the first analysis is called the T
method and the second is termed the Gaussian method. Figure 2(a) pro-
vides plots of actual false discovery rates against the desired false discovery
rates, which was used in Lo and Gottardo (2007). Figure 2(b) shows plots
of the true positive rates against the false positive rates. It is clear from
Figures 2(a) and (b) that the method allowing t-distribution and shRNA
specific variance performs much better.
The second data set is generated by the same model parameters as the
first data set except ωxij = ωyij = 1, σ
2
xi = 0.1, and σ
2
yi = 0.5; thus, the error
terms are normal with the same variance. This data set is again analyzed by
the above-mentioned T method and the Gaussian method and a comparison
of the two is summarized in Figure 3. We can see that the Gaussian method
performs only slightly better.
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(a) (b)
Fig. 2. Comparison of the results analyzed by the T method and the Gaussian method,
based on data generated from t-distributions with J = 2. (a) The actual FDR versus the
desired FDR; (b) the ROC curves.
(a) (b)
Fig. 3. Comparison of the results analyzed by the T method and the Gaussian method,
based on data generated by normal distribution with J = 2. (a) The actual FDR versus the
desired FDR; (b) the ROC curves.
The third data set is generated in the same way as the first except that
the number of replicates J = 10. Figure 4 compares the results obtained
from the data with J = 2 and J = 10, both of which are analyzed by the T
method of this paper. Figure 4 shows that the results using J = 10 is much
better than J = 2.
In fact, we also compared these two methods using data generated with
error terms being neither Gaussian nor t-distributed and observed results
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(a) (b)
Fig. 4. Comparison of the results with J = 2 and J = 10, based on data generated from
t-distributions and analyzed by the T method. (a) The actual FDR versus the desired FDR;
(b) the ROC curves.
similar to those in Figures 2 and 4. To keep the paper concise, we omit
reporting these comparisons.
4. Data preprocessing. Data preprocessing for RNAi HTS usually con-
sists of three parts: edge effect adjustment, normalization to reduce plate
effects, and outlier removal. Several data preprocessing methods have been
proposed to deal with these issues; see, for example, Boutros, Bras and Hu-
ber (2006), Malo et al. (2006) and Zhang et al. (2006). These methods are
adapted to suit the present experiment.
The following three observations motivate our data preprocessing pro-
cedure. The first observation is that technically replicated measurements
should be close to each other; this provides an opportunity to evaluate the
general quality of the experiment as well as to eliminate shRNAs showing
large discrepancy between the replicated measurements. The second obser-
vation is that the assignment of a shRNA to a well and the effect of this
shRNA on the measurements are independent; our edge-effect adjustment
makes use of this observation. The third observation is that measurements
of control wells of the same type are expected to be close to each other;
the measurements for NTNP wells are expected to be larger than those for
SN wells and those for NTWP wells are expected to have the smallest mea-
surements; violation of these indicates poor quality of the experiments. In
the HCV study, no such violation is observed in any single plate either for
luciferase activity or cell viability; our normalization procedure makes use
of this observation.
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Our data preprocessing are performed by first conducting edge effect ad-
justment and selecting the control wells so as to perform normalization, and
then deleting the outliers. The final data in the analysis consists of 6,130
shRNA and 419 negative control wells, each of which has four replicates.
Control wells serve two purposes in our data preprocessing. Since the
measurements for NTNP wells are larger than those for SN wells and NTWP
wells have the smallest measurements in any plate, it seems a good idea to
use these control wells to perform normalization if we can first delete outliers
in the control wells. This outlier deletion is carried out for luciferase activity
and cell viability separately. Here we present the deletion criterion for the
luciferase activity in a shRNA or control well; that for cell viability is similar
and omitted. Using the fact that there are four platewise replicates with two
of them measuring luciferase activity, we consider the ratio of the difference
of its two replicated measurements to its mean for a given well position, and
delete both of its luciferase activities for a given well position if the ratio is
large. For the HCV study data, two NTNP control wells were deleted based
on the cell viability measurement before normalization.
Edge effect exists in both the measurements of luciferase activity and cell
viability; the same adjustment procedure is carried out separately for each
of these two measurements and described as follows. We partition all the
wells in this experiment into three groups: G1 consists of all the wells on the
boundary of a plate; G2 consists of all the wells not in G1 but immediately
adjacent to wells in G1; G3 the remaining wells. A fixed constant is added
to the measurement from each well in G2 so that the average of all the
measurements from wells in G2 is equal to that from wells in G3; a similar
procedure is applied to the measurements from each well in G1, except
those from NTWP control wells. The rationale for not performing edge effect
adjustment to the NTWP control wells is that the total numbers of cells in
these wells are very small already and we expect little edge effects there. We
note that all the control wells are in G1.
After the outliers in the controls have been removed and the edge effect
has been taken into account, we perform normalization to reduce the plate
effect. The same normalization procedure is done separately for luciferase
activity and cell viability; we describe the procedure for luciferase activity
and omit that for cell viability, because of the similarity. Our normalization
will, in particular, make mean measurements of the controls of the same type
in each plate taking the same value for different plates. The procedure is as
follows. We denote the mean measurements of NTNP wells, SN wells, and
NTWP wells in plate h by ah, bh, and ch, respectively. Let a, b, and c denote,
respectively, the mean measurements of all of the NTNP wells, SN wells,
and NTWP wells from all the plates in this experiment. The normalization
procedure for wells in plate h is accomplished by using the unique continuous
piecewise linear function that maps ah, bh, and ch to a, b, and c, respectively.
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Namely, its value at x is

x− ch + c, if x≤ ch;
(a− c)(x− ch)/(ah − ch) + c, if ch < x≤ ah;
(b− a)(x− ah)/(bh − ah) + a, if ah < x≤ bh;
x− bh + b, if bh < x.
The luciferase activity of a well in plate h is to be replaced by the value of
the piecewise linear function at that luciferase activity. In the plates without
NTWP wells, the normalization is carried out using the piecewise linear
function defined by a and b.
After normalization, we exclude a shRNA from the analysis if either the
ratio of the difference of its two replicated luciferase activity to its mean or
the ratio corresponding to its two replicated cell viability measurements is
large. For each of the two measurements, we excluded two percent of the
shRNAs that have the most extreme ratios in the HCV study.
5. The HCV study. We now apply our methods to analyze the HCV
study data. In particular, we will provide lists of candidate shRNAs causing
the reduction of HCV replication without changing cell viability. We will first
explain in some detail the way we apply the methods in analyzing the data
and the way we use part of the control wells to evaluate the performance of
the methods. We will also examine our methods in light of a limited Q-PCR
experiment, compare with the results using the standard Z-score approach,
show that our Bayesian analysis is insensitive to the choice of prior, and
indicate that there does exist concordance between our findings and those
in Supekova et al. (2008) and Tai et al. (2009).
5.1. Data analysis. After the data preprocessing procedures, we ana-
lyzed the data using the Bayesian method of this paper. Following the data
analysis strategies described in Section 2, we choose φ1 = φ2 = 0.03 and
φ3 = φ4 = 0.2. In fact, {(xi1 − xi2)2/2|i= 1, . . . ,6,549} has mean 0.0016 and
variance 8× 10−6 and {(yi1 − yi2)2/2|i= 1, . . . ,6,549} has mean 0.0107 and
variance 0.0004. Except for the sensitivity analysis in Section 5.5, we always
use φ5 = 9, φ6 = 1, φ7 = 3, and φ8 = 1.9× 105 in this section. We note that
IG(·|3,1.9× 105) has mean 95,000 and variance 9.025× 109.
We use about half of the SN and NTNP wells and all of the NTWP wells
for normalization purposes and use the remaining control wells to evaluate
our analysis method and to help decide the knockdown effects of specific
shRNAs. In each plate, there is about one NTWP well, two SN wells, and
three NTNP wells. We use all the NTWP wells for normalization. We also
note that there are in total 71 plates and 426 control wells in one replicate
and there are four platewise replicates, as described at the end of Section 1.1.
After the initial outlier deletion of 2 NTNP controls, we use 277 controls
for normalization. The outlier deletion step after normalization excluded
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Fig. 5. The volcano plot of posterior activity change coefficient and posterior probability
of activity change for the HCV study.
another 6 controls, three of which were among those used for normalization
earlier. These outliers are excluded from the analysis. It turns out that our
analysis includes 419 controls, 274 of which were used for normalization and
the remaining 145 controls are used to evaluate our methods as well as to
decide the knockdown effect of specific shRNAs.
The posterior distributions are obtained by the hybrid MCMC algo-
rithm in the supplementary material [Chen et al. (2011)]. We calculated
the Gelman–Rubin statistic Rˆ for all the important estimands based on five
chains with random initial values in several studies and found all the Rˆ’s
were less then 1.1 using the iterations between 10,000 and 20,000. Based
on this experience and the fact that all the studies in this section involve
similar computations, we run one chain with 40,000 iterations and use the
latter 20,000 iterations to calculate the posterior distributions of all the
parameters in each study.
Figure 5 gives some idea of the distribution of the activity change in
this experiment. Each dot in Figure 5 gives the results of one shRNA; its
vertical coordinate gives its posterior probability of incurring activity change
1− pi and its horizontal coordinate gives its magnitude of activity change
E(βi|γi = 1, x, y), given there is activity change. E(βi|γi = 1, x, y) is also
called the posterior activity change coefficient. Figure 5 indicates a very
clear relation between these two quantities and it will be clear that both are
useful in examining the activity change.
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Fig. 6. The Scatterplot of predictive versus realized χ2 discrepancies for the HCV study.
Figure 6 gives the graphical display of the posterior predictive check that
using the χ2 omnibus discrepancy test quantity,
6,549∑
i=1
2∑
j=1
(yij −α0 − γiβi − α1xij)2
α21σ
2
xidx/(dx − 2) + σ2yidy/(dy − 2)
.
The concept of posterior predictive check appeared in Gelman, Meng and
Stern (1996); see also Gelman et al. (2003). Figure 6 seems to indicate that
the model fits the data quite well. In fact, in the choice of priors, we find
large φ8 not only makes V less informative but also make model fit possible.
By the way, the posterior means of α0, α1, V , dx, and dy are, respectively,
12.557, 2.538, 58.207, 30, and 10.
We may regard the minimal interval containing the posterior means of
the cell viability E(µi|x, y) of the 274 controls as the range of normal cell
viability, which is (−0.635,−0.007), although this definition of normal cell
viability might be a little too stringent. Nevertheless, we find all of the re-
maining 145 controls are in this normal range. This finding seems to suggest
that our methods give good estimates of the cell viabilities. Among all the
6,130+419 = 6,549 wells, 5,862 have their cell viabilities in the normal range,
602 of them less than −0.635 and 85 of them larger then −0.007.
Figure 7 reports two histograms of the probability of activity change 1−pi.
The dark one, called Histogram 7(a), is the histogram for the 145 controls;
the light one, called Histogram 7(b), is that for all the 6,549 wells. Since His-
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Fig. 7. Histogram of posterior probability of activity change 1− pi. The dark histogram,
referred to as Histogram 7 (a), is for the 145 control wells reserved for evaluation purposes.
The light histogram, referred to as Histogram 7 (b), is for all the 6,549 wells.
togram 7(a) concentrates heavily on the left, we think our methods assigned
appropriate posterior probability to these 145 control wells.
In fact, Histogram 7(a) provides opportunities for the study of false dis-
covery rate. For this, we present the data of Histogram 7(a) in Figure 8 using
finer resolution so as to exhibit more details. Figure 8 seems to suggest that
the set of shRNAs having 1− pi larger than 0.2532, 0.1055, or 0.05 has false
discovery rate, respectively, 0, 1/145, or 2/145, among others.
There is still another quantity that is useful in assessing the perfor-
mance of our methods, namely, the posterior activity change coefficient
E(βi|γi = 1, x, y). Figure 9 provides two histograms of posterior activity
change coefficient; the dark one, sitting above the interval (−0.806,0.392),
is that for the 145 shRNAs in the control wells and the light one, sitting
above the interval (−4.081,1.967), is that for the total set of 6,549 shRNAs.
The fact that the former sits in the middle of the latter, as expected, seems
to give another piece of indication that the experiment and data analysis
are reliable.
5.2. Main results. We are now in a position to provide shRNA lists, based
on which the laboratory scientists can conduct experiments to identify those
that affect HCV replication without affecting cell viability. Knowing that
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Fig. 8. Histogram of the posterior probability of activity change 1−pi for the 145 control
wells.
among the 785 shRNAs having their E(βi|γi = 1, x, y) less than −0.806, 601
of them have their cell viability in the normal range (−0.635,−0.007), we will
start the selection with this set of 601 shRNAs. For this, we will make use of
the direct posterior probability approach discussed in Newton et al. (2004).
Assuming that placing a shRNA having posterior probability of not in-
curring activity change pi in the list for further studies creates a loss of the
amount pi, we rank the shRNAs according to their pi and form the list as
follows. Given a set ς of shRNAs for which the losses are less than a positive
number κ, we define
C(κ) =
∑
i
pi1[pi<κ],
which is the sum of the losses for all the shRNAs in ς . We note that C(κ)/|ς|
is called the posterior false detections rate (PFDR), where |ς| is the size of
the set ς ; we also note that with the shRNAs ordered by pi, there is a natural
correspondence between κ and set size |ς| and that C(κ)/|ς| increases with κ.
To obtain a list of shRNAs having PFDR C(κ)/|ς| less than α, we can find
the largest possible κ or |ς| such that C(κ)/|ς| is less than α. In practice,
we can either fix the list size and then compute its PFDR or fix the PFDR
and compute the list size. For the set of 601 shRNAs having normal cell
viability and posterior activity change coefficient less than −0.806, Table 1
is a summary of various lists of shRNAs. Its left column reports PFDR by
first fixing the set size and its right column reports list size by first fixing
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Fig. 9. Histogram of posterior activity change coefficients. The dark histogram is for the
145 control wells. The light histogram is for all the 6,549 wells.
the PFDR. For example, the second row in the left column says that the
list of top 100 candidate shRNAs, targeting 77 genes, has PFDR 0.047; the
second row of the right column says given PFDR being 0.05, the list has
104 shRNAs, targeting 81 genes, and one of the genes has three of the 104
shRNAs targeting it, 21 of the genes have two such shRNAs targeting each
of them and the remaining 59 genes have only one such shRNA targeting
each of them.
Table 1
Posterior false detection rates for lists of shRNAs whose E(µi|x, y)∈ (−0.635,−0.007)
and E(βi|γi = 1, x, y)<−0.806 in the HCV study
Fix list size Fix PFDR
Number of
genes (shRNAs)
Number of
genes (shRNAs)
Number of shRNAs
PFDR PFDR 5 4 3 2 1
0.024 40 (50) 0.01 20 (21) 1 19
0.047 77 (100) 0.05 81 (104) 1 21 59
0.106 151 (200) 0.10 144 (190) 2 6 27 109
0.174 210 (300) 0.20 234 (337) 1 3 15 57 158
0.242 271 (400) 0.30 309 (488) 3 7 31 79 189
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We note that when we are interested in individual shRNAs, those in the
first row are better candidates than those in the other rows; when we are
interested in genes that affect HCV replication, then we need to consider
the number and the knockdown effects of all the shRNAs in each gene. We
will illustrate the latter in Section 5.6.
Tai et al. (2009) pointed out the issue of the choice of threshold in the
Z-score approach to hit selection; higher threshold causes little overlap with
other studies and lower threshold results in too many siRNAs for secondary
validation. Our approach benefits from not only the statistical model but also
the negative controls. The above analysis points out an issue regarding the
number of negative controls to be used for the false discovery rate estimate.
We believe that if we had more negative controls, we could have provided
more information, including false discovery rate, for the selection of shRNAs
or genes.
For the purpose of comparison in Sections 5.4 and 5.6, we say a shRNA in
the HCV study causes activity change if either its pi < 1− 0.2532 = 0.7468
or its E(βi|γi = 1, x, y) /∈ [−0.806,0.392]; a shRNA has normal cell viability
if its E(µi|x, y) ∈ (−0.635,−0.007).
5.3. Q-PCR validation. Q-PCR is one of the popular methods to study
activity change in a secondary analysis of a gene list from a primary RNAi
HTS. In this study, both HCV RNA and house-keeping gene beta-actin are
reverse transcribed and then quantified using Q-PCR in a well with a given
shRNA or without any shRNA transduction. The ratio of the quantity of
HCV RNA in a well with the shRNA transduction to that in a well without
any shRNA transduction and the corresponding ratio for beta-actin are first
calculated; the former ratio divided by the latter ratio gives the activity
change measured by Q-PCR for shRNA i, which is denoted by ki.
When ki is around 1, we may say there is no activity change; when it
is large (small), we may say it increases (decreases) the activity. Although
Q-PCR is considered to provide reliable measurements, we do not know
of a good threshold on ki for declaring activity change. Thus, we choose to
present the correlation between the activity ki reported by the Q-PCR assay
and posterior activity change coefficient reported by our methods as a way
to make the comparison.
We examined by the Q-PCR method the pathway activity of 86 shRNAs
in the HCV study; we note that 68 of them have their ratio for beta-actin
belonging to the interval (0.7,1.43); these 68 shRNAs may thus be considered
to have less appreciable effect on cell viability. The empirical correlations of
these two assays are 0.68 for all these 86 shRNAs and 0.77 for the 68 shRNAs
not affecting cell viability. We note that these 86 shRNAs had been chosen
for Q-PCR assay before the methods of this paper were proposed. We note
that we do not expect perfect correlation, because, for HCV replication, our
RNAi HTS monitors the luciferase protein and Q-PCR measures HCV RNA
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and, for cell viability, ours monitors the level of dehydrogenase and Q-PCR
montiors the level of mRNA of beta-actin.
5.4. Comparison with the Z-score approach. Platewise Z-score is often
used in the primary analysis of RNAi HTS data; see, for example, Tai et al.
(2009). In particular, Tai et al. (2009) says that “A Z-score is the number
of standard deviations of the experimental luciferase activity above the me-
dian plate value.” Because the plate effect in the data from the HCV study
has been reduced by normalization, it seems appropriate for us to consider
an experiment-wise Z-score and compare this Z-score approach with the
method of this paper. We define the Z-score as
Zij =
yij −Mj
Sj
.
Here Mj and Sj are, respectively, the median and standard deviation of
{yij |i= 1, . . . , I} for j = 1,2, after data preprocessing procedures.
Hit selection based on Z-score chooses shRNAs having extreme Z-scores.
It is desirable that these Z-scores follow a normal distribution; in this case,
we can conveniently assign a p-value to Zi = (Zi1+Zi2)/2 and use p-value to
describe the extremeness of the selected shRNA. Figures 10(a) and (b) give,
respectively, the plot of (Zi1,Zi2) and the histogram of {Zi|i= 1, . . . , I} for
the HCV study. While Figure 10(a) shows that Zi1 and Zi2 have correlation
0.990 and are in good agreement, indicating both the assay and the data
preprocessing procedure are excellent, Figure 10(b) suggests they are not
normally distributed.
(a) (b)
Fig. 10. Scatter plot for Z-scores and histogram of Z-score mean. (a) The scatter plot
for (Zi1,Zi2); (b) the histogram of Zi = (Zi1 +Zi2)/2.
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Fig. 11. Plot of the Z-score vs posterior activity change coefficient for 86 shRNAs. The
shRNAs that show largest discrepancy between the Z-score and posterior activity change
coefficient target, respectively, RPS6, KIAA1446, INPP4A, SFRS1, and TYK2. The nu-
merals in the figure correspond to those in Table 2.
For the above set of 86 shRNAs assayed by Q-PCR and whose subset
of 68 shRNAs are not affecting cell viability, we find the empirical correla-
tions of their Z-scores Zi and the activity change measured by Q-PCR ki
are 0.62 and 0.72, respectively. Compared with the correlations reported in
Section 5.3, it seems that the activity change computed by our method is in
better agreement with those reported by the Q-PCR method.
Figure 11 is the plot of the Zi versus E(βi|γi = 1, x, y) for the 86 shRNAs.
The five shRNAs that show largest discrepancy between the Z-score Zi and
posterior activity change coefficient target five genes: RPS6, KIAA1446,
INPP4A, SFRS1, and TYK2; this discrepancy is decided by the size of
the residues when a linear regression is fitted. Table 2 reports the posterior
probability of activity change, posterior activity change coefficient, posterior
mean of cell viability E(µi|x, y), Z-score Zi, and Q-PCR activity change ki
for these five shRNAs showing largest discrepancy. All these methods claim
unequivocally and unanimously that the shRNA targeting RPS6 decreases
the pathway activity significantly. In fact, we have verified that RPS6 is
a crucial factor for HCV and we are preparing a manuscript for this find-
ing. Both Q-PCR and our method claim that the one targeting KIAA1446
increases the activity of the pathway and that targeting INPP4A has little
effect on the pathway, while the Z-score approach suggests differently; for
SFRS1, Q-PCR seems to claim a mild increase of the pathway activity, our
method suggests little effect on the pathway activity and Z-score suggests
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Table 2
The Z-score, posterior activity change coefficient, and Q-PCR activity change effect ki
for five shRNAs
Gene 1− pi E(βi|γi = 1, x, y) E(µi|x, y) Zi ki
75 RPS6 0.993 −2.323 −0.657 (8.80%) −3.067 0.08
66 KIAA1446 0.491 0.973 −0.657 (8.81%) −0.134 2.59
28 INPP4A 0.005 −0.088 −1.065 (6.00%) −1.925 1.25
27 SFRS1 0.005 −0.111 −0.975 (6.41%) −1.719 1.83
46 TYK2 0.907 −1.542 −0.650 (8.95%) −2.317 1.33
a decrease in pathway activity; for TYK2, Q-PCR suggests little effect and
both our method and Z-score suggest a decrease in pathway activity. Ta-
ble 2 seems to suggest again that our method is in better agreement with the
Q-PCR method in reporting the activity change effects of shRNAs. We note
that the percentage in the cell viability in Table 2 shows the corresponding
percentile among all the 6,549 wells.
5.5. Sensitivity analysis. This subsection examines certain distributional
assumptions on the prior used in Section 5.1 for analyzing the HCV study
data. The prior on p used was Beta(9,1); we now also consider Beta(1,1).
The prior on µi was U(−3,1); we now also consider the empirical one
(0.248 + 2.77) · Beta(6,2)− 2.77. Thus, there are four combinations in these
comparisons, with all the other analysis strategies unchanged. We report
here three posterior inferences for the comparison of these four studies. In
fact, we made extensive comparisons and found only similar results and the
three reported here are the most representative ones. Table 3 treats the
posterior probability of activity change based on the 145 controls. That all
these probabilities in Table 3 are close to zero shows that all of them perform
very well, just as the one in Section 5.1. Table 4 reports the correlation be-
tween the probability of activity change obtained from one combination and
that obtained from another. Table 5, like Table 4, reports the correlation
regarding the posterior activity change coefficient obtained from different
Table 3
Posterior probability of incurring activity change 1− pi for the 145 control wells
Prior on p Beta(9,1) Beta(1,1)
Prior on µi Empirical prior Uniform prior Empirical prior Uniform prior
Median 0.0045 0.0068 0.0043 0.0038
75% quantile 0.0095 0.0155 0.0078 0.0065
Maximum 0.1275 0.2532 0.1098 0.0955
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Table 4
Correlations between the posterior probability of activity change obtained from one prior
combination and that from another
Prior on p Beta(9,1) Beta(1,1)
Prior on µi Empirical prior Uniform prior Empirical prior
Beta(9,1) Empirical prior
Uniform prior 0.972
Beta(1,1) Empirical prior 0.997 0.960
Uniform prior 0.992 0.946 0.995
Table 5
Correlations between the posterior activity change coefficient obtained from one prior
combination and that from another
Prior on p Beta(9,1) Beta(1,1)
Prior on µi Empirical prior Uniform prior Empirical prior
Beta(9,1) Empirical prior
Uniform prior 0.990
Beta(1,1) Empirical prior 0.992 0.988
Uniform prior 0.990 0.988 0.989
analyses. Since all of the correlations in Table 4 and Table 5 are larger than
0.94, it seems that the posterior inferences are not sensitive to these aspects
of the prior assumptions.
5.6. Some comparison with the literature. Cherry (2009) reviewed five
papers that use siRNA screens to identify cellular factors that impact repli-
cation of HCV or subgenomic replicons and found little overlap between
them. As part of our effort to evaluate the performance of our method, we
select all the siRNAs in our list that show activity change in Supekova et al.
(2008) and Tai et al. (2009) and see whether our findings are in line with
theirs. A comprehensive discussion of the scientific findings of our study will
be reported elsewhere.
Supekova et al. (2008) reported that siRNAs specific for three human
kinases, CSK, JAK1, and VRK1, were identified to reduce the replication
of HCV; they also reported that by examining the siRNA knockdown effect
of the eight kinase genes in the Src family (BLK, HCK, FGR, LCK, LYN,
FYN, c-SRC, and YES) on the HCV replicon, they found that their siRNAs
targeting seven of them did not show any effect and that targeting FYN
elevated replicon levels by about 3-fold upon transduction.
In our HCV study, there are shRNAs targeting nine of these 11 genes,
except c-SRC and YES. We now compare our results on these nine genes
with those from Supekova et al. (2008).
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Among the five shRNAs targeting FYN, four of them indicated consider-
able elevation in HCV replication and the other one did not show activity
change; none showed change in cell viability. Our screening showed also that
none of the shRNA targeting FGR or HCK indicated any appreciable activ-
ity change. These results are in perfect or excellent agreement with those in
Supekova et al. (2008).
Among the four targeting BLK, three of them showed no activity change
and one indicated considerable increase; among the five targeting LCK, four
of them showed no activity change and one indicated considerable decrease.
These are in partial agreement with Supekova et al. (2008).
Among the 10 shRNAs targeting CSK, one showed considerable decrease
both in HCV replication and in cell viability; another showed considerable
decrease in HCV replication without change in cell viability; still another
showed considerable increase in HCV replication without change in cell via-
bility; the remaining seven showed no change. All the four targeting JAK1
indicated no activity change and no cell viability change. None of the two
targeting VRK1 indicated any appreciable activity change, although one
of them indicated considerable reduction in cell viability. Among the five
shRNAs targeting LYN, three of them indicated strong elevation in HCV
replication without appreciable change in cell viability. These suggest a cer-
tain amount of disagreement between our findings and those in Supekova
et al. (2008).
In view of the general lack of concordance between results of similar HCV
screens in the literature, the amount of agreement between Supekova et al.
(2008) and our study seems encouraging.
We note that Tai et al. (2009) reported that there is little overlap between
the results of their screen and those of Supekova et al. (2008); in fact, none
of the three genes CSK, JAK1, and VKR1 were selected in the primary
screening of Tai et al. (2009), which seems to be in agreement with ours.
We now compare our results with Tai et al. (2009), in which 96 genes
are chosen from the primary screening for reduced HCV replication. In the
shRNA list of our study, there are shRNAs targeting four of these 96 genes;
they are TBK1, NUAK2, COASY, and MAP3K14.
Two of the four shRNAs in our list targeting MAP3K14 showed strong
reduction in HCV replication, another indicated marginal reduction in HCV
replication and the fourth one indicated no activity change; none showed
change in cell viability. The shRNAs targeting the remaining three genes
showed little effect on the reduction of HCV replication. We note that Tai
et al. (2009) used 21,094 siRNA pools targeting the entire human RefSeq
transcript database; each of these pools consists of four individual siRNA
duplexes and each of these four siRNAs targets a different sequence within
the target transcript.
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6. Discussion. We have presented a Bayesian method to analyze data
from two channel cell-based RNAi HTS experiments with replicates, in which
the phenotype of a pathway-specific reporter gene and that of a constitutive
reporter are measured. These experiments are typical in screens for signaling
pathway components and the purpose is often to identify genes that affect
the activity of the specific pathway without affecting that of the constitutive
reporter.
We have conducted simulation studies and real data analysis to illustrate
the methods. Our simulation studies indicate that error terms with shRNA
specific t-distribution do make the method flexible and robust and that
replication provides better power in identifying shRNAs of interests and, at
the same time, gives better estimates of the false discovery rates.
In our analysis of the real data set, we illustrate the usage of negative
controls, included originally for normalization purposes only, to assess the
performance of our methods, to estimate false discovery rate, and to priori-
tize the shRNAs for secondary validation, in addition to hit selection; we find
our methods perform excellently and these negative controls are very useful.
We have also conducted a Q-PCR based assay to assess the activity change
of 86 shRNAs; we find the results based on Q-PCR are in better agreement
with those based on our method than with those based on the standard
Z-score approach. We have also shown that our method is insensitive to the
choice of prior. Finally, it is encouraging to find that there does exist some
overlap between the results of the HCV study and those of Supekova et al.
(2008) and Tai et al. (2009).
Realizing the usefulness of negative controls, we are interested in knowing
the optimal number of negative controls to be included in an experiment.
It seems also desirable to include positive controls as well in the experi-
ment. With both positive and negative controls, we may extend our Bayesian
method so as to improve our report on the false positive and negative rates
in a RNAi HTS. We note that characteristics of these controls, especially
positive controls, and the number of these controls deserve serious attention
in designing an experiment and in extending our statistical method.
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SUPPLEMENTARY MATERIAL
A Computer algorithm for analyzing data from two-channel cell-based
RNAi experiments with replicates (DOI: 10.1214/11-AOAS496SUPP; .pdf).
This note provides the hybrid MCMC algorithm for sampling the posterior
distribution used in Chen et al. (2011) and several observations used in
designing this algorithm so as to make it more efficient.
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